ASH1L and neoplasm: By epigenetically reprogramming invading cancer cells, ASH1L not only induces tumor-infiltrating monocyte differentiation into lipid-associated and angiogenic TAMs, but also suppresses antigen presentation, interferon signaling, and immunostimulatory molecule expression in inflammatory TAMs.